Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug ...

“Steroid withdrawal has had a massive impact on my life ... Fortunately, there are eczema treatment alternatives to steroid creams. Interleukin (Dupixent) and JAK (Rinvoq) inhibitors are excellent ...

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria. The approval is for patients 12 years and ...

In 2024, Dupixent sales came in at $14.1 billion, which was an increase of 22% from 2023. Dupixent’s trajectory contributed heavily to Sanofi’s strong quarterly performance.

Sales of its blockbuster asthma drug Dupixent rose 20.3% to 3.48 billion euros, compared with 3.44 billion euros expected on average by analysts. Sales of Beyfortus, a new treatment to protect ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria (CSU), a condition that causes painful hives that often don't respond to ...

In two clinical studies, Dupixent showed reductions in itch severity and urticaria activity at 24 weeks, as well as an increased likelihood of well-controlled disease or complete response at 24 ...

All growth rates mentioned below are on a year-on-year basis and at CER. In Immunology, Dupixent generated sales of €3.48 billion in the quarter, up 20.3% year over year, driven by strong ...